Irish-founded hVIVO lands €7.5m contract to test vaccines

hVIVO, an Irish-founded research organisation, has signed a major contract worth £6.8 million (€7.6 million) to test vaccines.

The company, formerly known as Open Orpahn, said the deal was with a “leading pharmaceutical company based in Asia Pacific”, however it did not name the business.

The contract is for hVIVO to test the company’s respiratory syncytial virus (RSV) antiviral drug candidate.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO